Real-World Outcomes of Patients Starting Intravenous and Transitioning to Subcutaneous Vedolizumab in Inflammatory Bowel Disease.

N LamichhaneN MelasV Bergqvistnull nullN-P EkholmO OlénJ F LudvigssonH HjortswangJ MarsalC ErikssonJonas Halfvarson

Published in: Digestive diseases and sciences (2024)

Initiating IV VDZ and switching to SC treatment was associated with high persistence rates and improvements in measures of QoL and FCP. These findings are reassuring for patients who start IV VDZ and switch to SC VDZ.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors
type diabetes
metabolic syndrome
adipose tissue
insulin resistance
patients with inflammatory bowel disease